FEN1 and neuroblastoma: This suggests that higher levels of FEN1 expression are associated with increased resistance to cisplatin treatment, implicating FEN1 as a potential biomarker for cisplatin sensitivity in NB and highlighting its relevance in therapeutic approaches for this malignancy.